Trial Profile
Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita / telomere disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2019
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary) ; Fludarabine (Primary)
- Indications Bone marrow disorders; Dyskeratosis congenita
- Focus Therapeutic Use
- 19 Jun 2019 Planned number of patients changed from 20 to 40.
- 10 Jul 2018 New trial record